Financing channel feed – Endpoints News

Financing channel feed

A Canadian startup refuels to take on a rare cardiac condition that many patients don't realize they have

4 years ago

Paragon's Harmony Biosciences brings in $330M of debt capital and equity, looking to expand narcolepsy drug label

4 years ago

Virtually unknown mRNA upstart rides SPAC to Nasdaq with a $1.5B valuation as RA-backed neuro player prices IPO

4 years ago

Tillman Gerngross steers a biotech unicorn to Nasdaq, while another company's IPO plans fizzle

4 years ago

Drug pricing disruptor EQRx makes the big leagues with $1.8B SPAC deal and a new CEO at the helm

4 years ago

Oxford spinout raises $113M in bid to beat Sarepta's Exondys 51 in DMD. But will we ever know if any of the drugs work?

4 years ago

Emerging from stealth mode, Aardvark rounds up enough cash to put its lead drug through Prader-Willi PhII

4 years ago

Zymergen's sudden implosion shocked biotech. A lingering loan could make things even worse

4 years ago

With clinical trials lined up for Zentalis drugs, China's Zentera sets its sights on more dealmaking and an IPO

4 years ago

What happens when you give a mouse a human self-antigen? Investors bet $110M to find out

4 years ago

Six more biotechs price public debuts just before the start of the weekend

4 years ago

Shooting straight for Venclexta, a seasoned Chinese CEO has global dreams for his startup

4 years ago

Royalty Pharma competitor stirs the pot with plans for $750M IPO

4 years ago

Three more companies price IPOs, bringing this year's raise up to $11.78B

4 years ago

As leading synbio players bask in spotlight, US/China startup lands $100M to find its own niche

4 years ago

Flush with cash, Rakuten billionaire Mickey Mikitani looks to take his photoimmunotherapy platform global

4 years ago

Merck and Pfizer back a Michigan startup's mission to advance tumor profiling

4 years ago

Deerfield and ARCH back a new $200M SPAC run by California VC firm

4 years ago

AstraZeneca castoff draws $123M wager on CXCR2 antagonist as Arena lines up a buyout option

4 years ago

Deep Genomics, now flush with cash, plans to take dozens of RNA therapies to the clinic

4 years ago

Looking to replicate Covid-19 success in neuro, BioNTech backers bet on AC Immune and its newly-acquired Parkinson's vaccine

4 years ago

Candel gets busy IPO week moving with downsized raise as Rajiv Shukla's third SPAC goes public

4 years ago

What will Lumira Ventures do with $220M? Stay out of the comfort zone and off the beaten biotech path

4 years ago

Novartis partner Artios bags megaround to drive clinical work on DNA damage repair factors

4 years ago

First page Previous page 68 69 707172 73 74 Next page Last page